Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SDT-M001
- Development stage
- Phase 1
- Lead developer
- Cytocraft Biopharmaceutical
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
SDT-M001 is an investigational cell therapy consisting of Cascade primed immune cells (CAPRI) developed by Cytocraft Biopharmaceutical Co., Ltd. It is being evaluated as an adjuvant treatment for non-small cell lung cancer (NSCLC) patients who are driver-gene-negative and have negative PD-L1 expression after radical surgical resection. The therapy is administered via injection, with cells reinfused in divided doses over several days.
- Other names
- SDTM001SDTM-001SDTM 001
Beyond the preview
Go deeper on SDT-M001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SDT-M001.